Combined simultaneous kidney/bone marrow transplantation.

On the basis of observations in patients with long-term (28-30 years) renal allograft survival, all of whom had evidence of systemic microchimerism, we began a program of combined simultaneous kidney/bone marrow transplantation. Between 12/14/92, and 10/31/94, 36 kidney transplant recipients received 3-5 x 10(8) unmodified bone marrow cells/kg; 6 patients also received pancreatic islets, and 7 patients also received a pancreas. The mean recipient age was 39.0 +/- 10.8 years, and the mean donor age was 31.8 +/- 16.1 years; the mean cold ischemia time was 23.0 +/- 9.1 hr. Twenty control patients received kidneys alone, mainly because of refusal by the donor family to consent to vertebral body recovery; 3 of these patients also received a pancreas. The mean recipient age was 47.9 +/- 11.7 years, and the mean donor age was 41.5 +/- 17.9 years; the mean cold ischemia time was 28.6 +/- 6.2 hr. All patients received tacrolimus-based therapy, without radiation, cytoreduction, or induction antilymphocyte preparations. Blood was drawn prior to and at regular intervals after transplantation for detection of chimerism and for immunologic studies. With a mean follow-up of 11.1 +/- 5.8 months, all 36 study patients are alive, and 33 (92%) have functioning allografts with a mean serum creatinine of 1.9 +/- 1.2 mg/dl and a BUN of 26 +/- 9 mg/dl. Graft vs. host disease was not seen in any patient. The incidence of rejection was 72%; 11% of the patients required OKT3 or ATG for steroid-resistant rejection. The incidence of CMV was 14%, and that of delayed graft function was 17%. A total of 18 (90%) control patients are alive, and 17 (85%) have functioning allografts, with a mean serum creatinine of 2.1 +/- 1.3 mg/dl, and a BUN of 30 +/- 13 mg/dl. The incidence of rejection was 60%, and 10% required OKT3 or ATG. CMV was seen in 15%, and delayed graft function in 20% (P = NS). In the study patients, chimerism was detected in the peripheral blood of 30 of 31 (97%) evaluable patients by either PCR or flow cytometry. In the control patients, chimerism was seen in 9 of 14 (64%) evaluable patients (P < .02). Decreasing donor-specific responsiveness was seen in 6/29 (21%) evaluable study, and 4/14 (29%) evaluable control patients (P = NS). We conclude that combined kidney/bone marrow transplantation is associated with acceptable patient and graft survival, augmentation of chimerism, and no change in the early events after transplantation.

[1]  S. Pham,et al.  Augmentation of chimerism in whole organ recipients by simultaneous infusion of donor bone marrow cells. , 1995, Transplantation proceedings.

[2]  A. Demetris,et al.  Combined bone marrow and whole organ transplantation from the same donor. , 1994, Transplantation proceedings.

[3]  A. Demetris,et al.  A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy. , 1994, Clinical transplantation.

[4]  A. Demetris,et al.  Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation , 1994, The Lancet.

[5]  J. Lemons,et al.  PERIPHERAL BLOOD CHIMERISM IN RENAL ALLOGRAFT RECIPIENTS TRANSFUSED WITH DONOR BONE MARROW1,2 , 1994, Transplantation.

[6]  T. Starzl,et al.  CHIMERISM AND DONOR‐SPECIFIC NONREACTIVITY 27 TO 29 YEARS AFTER KIDNEY ALLOTRANSPLANTATION , 1993, Transplantation.

[7]  T. Starzl,et al.  Cell migration and chimerism after whole‐organ transplantation: The basis of graft acceptance , 1993, Hepatology.

[8]  T. Starzl,et al.  Cell migration, chimerism, and graft acceptance , 1992, The Lancet.

[9]  T. Starzl,et al.  HUMAN ISLET ISOLATION AND ALLOTRANSPLANTATION IN 22 CONSECUTIVE CASES 1, 2 , 1992, Transplantation.

[10]  S. Knechtle,et al.  Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. , 1991, Transplantation proceedings.

[11]  O. Salvatierra,et al.  A SEVEN‐YEAR EXPERIENCE WITH DONOR‐SPECIFIC BLOOD TRANSFUSIONS; Results and Considerations for Maximum Efficacy , 1985, Transplantation.

[12]  D. Sachs,et al.  Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts , 1984, Nature.

[13]  J. Thomas,et al.  Long-term incompatible kidney survival in outbred higher primates without chronic immunosuppression. , 1983, Annals of surgery.

[14]  Z. Fuks,et al.  Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts , 1977, The Journal of experimental medicine.

[15]  A. Monaco,et al.  Enhanced survival of canine renal allografts of ALS- treated dogs given bone marrow. , 1973, Transplantation proceedings.

[16]  R Storb,et al.  Technique for human marrow grafting. , 1970, Blood.

[17]  R. Prehn,et al.  Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. , 1955, Journal of the National Cancer Institute.

[18]  B. Julian,et al.  Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. , 1991, Transplantation.

[19]  H. Deeg,et al.  Graft-versus-host disease: pathophysiological and clinical aspects. , 1984, Annual review of medicine.

[20]  J. Bagdade,et al.  Effects of chronic uremia, hemodialysis, and renal transplantation on plasma lipids and lipoproteins in man. , 1976, The Journal of laboratory and clinical medicine.